Instem plc [INS.L] Stock Forecast

Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Logbook, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities in non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; SEND Explorer, a web-based application with optional data warehousing capabilities; SENDTrial, a web based solution that can be accessed through a subscription; and standard for exchange of nonclinical data solutions. Further, the company provides Sorcerer Colony Counter for automatic plate counter; sales support, training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; and software solutions to extract intelligence from research and development related healthcare data. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.